TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled Study
Ciarán P. Kelly(Beth Israel Deaconess Medical Center), Mark S. Turner, Michael S. Boyne(Astellas Pharma (United States)), Amy Morris(Astellas Pharma (United States)), Mark Matson, Seppo Meri(University of Helsinki), M. Roy First(Astellas Pharma (United States)), Daniel A. Leffler(Beth Israel Deaconess Medical Center), Robert Fogel, Barbara Rizzardi, Adam C. Bledsoe(Mayo Clinic), Michele Gerber, Jocelyn A. Silvester, Adam Elhofy(Astellas Pharma (United States)), Paul K. Haynes, Glennda Smithson(Takeda (United States)), Daniel R. Getts(Northwestern University), Tobias Freitag, Michael Koren(Jacksonville University), Stephen D. Miller(Northwestern University), Joseph A. Murray, Joseph R. Podojil(Northwestern University), Tsung‐Teh Wu(Mayo Clinic), Thomas H. Oliphant
Cited by 177
Related Papers
Microglia Initiate Central Nervous System Innate and Adaptive Immune Responses through Multiple TLRs
|The Journal of Immunology|2004|1.2k
Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology
|Gut|2014|1.1k
Increased Prevalence and Mortality in Undiagnosed Celiac Disease
|Gastroenterology|2009|769
Body-Mass Index and Symptoms of Gastroesophageal Reflux in Women
|New England Journal of Medicine|2006|664